Applying the concepts of financial options to stimulate vaccine development

Vanessa Rato · Nature reviews. Drug discovery · 2006

Summary

This work offers an alternative approach to stimulating research into neglected diseases based on the concept of a financial call option that allows the purchaser to make payments during the early stages of development in exchange for reduced future prices.

Type: dissertation
Published: 2006-08-01
Cited by: 20
References: 32
Access: Open access
DOI: https://doi.org/10.1038/nrd2035
PubMed: https://pubmed.ncbi.nlm.nih.gov/16883302/
OpenAlex: https://openalex.org/W16883302
Semantic Scholar: https://api.semanticscholar.org/CorpusID:30088677

Keywords

Humanities, Philosophy

References

Making Practical Markets for VaccinesDonald W. Light — 2005
Valuation of a Biotechnology Firm: An application of real-options methodologiesD. W. Kellogg, John M. Charnes, Rıza Demirer — 1999
Patents and R&D Incentives: Comments on the Hubbard and Love Trade Framework for Financing Pharmaceutical R&DJoseph A. DiMasi, Henry G. Grabowski — 2004
Providing Global Public Goods: Managing GlobalizationInge Kaul — 2003
Putting a price on biotechnologyJeffrey J Stewart, P. Allison, Ronald S. Johnson — 2001
Real Options Based Analysis of Optimal Pharmaceutical Research and Development PortfoliosMichael Rogers, Anshuman Gupta, Costas D. Maranas — 2002
Vaccine visions and their global impactBarry R. Bloom, Roy Widdus — 1998
Decision analysis and drug development portfolio management: uncovering the real options value of your projectsNicoletta Rosati — 2002
A Markup Interpretation of Optimal Investment RulesAvinash Dixit, Robert S. Pindyck, Sigbjørn Sødal — 1999
Vaccine R&D success rates and development timesMark-M. Struck — 1996
Stimulating pharmaceutical research and development for neglected diseases.Monique F. Mrazek, Elías Mossialos — 2003
Shareholder Value, Real Options, and Innovation in Technology‐Intensive CompaniesAxel J. Jägle — 1999
A Model of R&D Valuation and the Design of Research IncentivesJason Hsu, Eduardo S. Schwartz — 2003
Capital allowances and the impact of corporation tax on investment in the UKStephen Bond, Kevin Denny, Michael Devereux — 1993
The price of innovation: new estimates of drug development costs.Joseph A. DiMasi, Ronald W. Hansen, Henry G. Grabowski — 2003
What's it worth? A general manager's guide to valuation.T A Luehrman — 1997
The Global Fund: managing great expectations.Ruairı́ Brugha, M. Donoghue, Mary Starling — 2004
Pharmaceuticals and the developing world.Michael Kremer — 2002
Optimal taxation as a guide to tax policy: a surveyChristopher Heady — 1993
The Promise and Peril of Real OptionsAswath Damodaran — 2005

Cited by

Evaluation of incentives for R&D in the pharmaceutical industry with applications for neglected diseasesEshref Trushin — 2011
Policies and Incentives for Promoting Innovation in Antibiotic ResearchElías Mossialos, Chantal Morel, Sally Edwards — 2010
The hope for neglected diseases: R&D incentivesBrigitte Granville, Eshref Trushin — 2010
Innovation Paradox in Vaccine Target SelectionE.S. Pronker — 2013
Pricing of new vaccinesBruce Y. Lee, Sarah M. McGlone — 2010
Stoking the antibiotic pipelineChantal Morel, Elías Mossialos — 2010
Incentives for new antibiotics: the Options Market for Antibiotics (OMA) modelDavid M. Brogan, Elías Mossialos — 2013
The Economics of an HIV/AIDS VaccinePatrick L. Leoni — 2014
A critical analysis of the review on antimicrobial resistance report and the infectious disease financing facilityDavid M. Brogan, Elías Mossialos — 2016
New Drugs to Tackle Antimicrobial Resistance: Analysis of EU Policy OptionsPriya Sharma, Adrian Towse — 2010
Why is the oral cholera vaccine not considered an option for prevention of cholera in India? Analysis of possible reasonsSanjukta Sen Gupta, Kaushik Bharati, Dipika Sur — 2016
IP-Based Incentives Against Antimicrobial Crisis: A European PerspectivePedro Henrique Dias Batista, Dennis Byrski, Matthias Lamping — 2019
Towards better diagnostic tools for liver injury in low-income and middle-income countriesSaundria Moed, Muhammad H. Zaman — 2019
COVID-19 vaccine challenges: What have we learned so far and what remains to be done?Rebecca Forman, Soleil Shah, Patrick Jeurissen — 2021
Vaccine Innovation Meta-Model for Pandemic ContextsBeatriz C. Fialho, Leandro Gauss, Priscila Ferraz Soares — 2023
A Strep A vaccine global demand and return on investment forecast to inform industry research and development prioritizationDonald R. Walkinshaw, Meghan E. E. Wright, Marni Williams — 2023
Product development partnerships (PDPs) for neglected diseases: considerations on governanceC. Sorenson — 2009
CSR to Increase Access to Medicines: Lessons and Opportunities for the Middle EastJ. Antoun — 2012
Stoking the antibiotic pipeline New antibiotics to tackle multidrug resistant bacteria are much neededC. Morel, Elias, Mossialos
Policies and IncentivesP. P. Reddy — 2012

Related papers

No related papers recorded.